Skip to content

The effects of D-serine supplementation on executive functions and related brain mechanisms.

The effects of D-serine supplementation on executive functions and related brain mechanisms.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083566
Enrollment
Unknown
Registered
2024-04-28
Start date
2024-04-30
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Excutive Function

Interventions

control group:Take placebo (corn starch) capsules two hours before the test
Supplementary group:Take 2g of D-serine in capsules two hours before the test.

Sponsors

Zhejiang Normal University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged 18 to 30, any gender. 2. Right-handed. 3. No physical or mental illnesses, no history of mental illness, no brain injury. 4. Normal vision or corrected vision. 5. Not color blind. 6. Participants are informed and consent to participate in this study voluntarily, and can adhere to the treatment plan.

Exclusion criteria

Exclusion criteria: 1. Allergic to medications 2. History of substance abuse or substance misuse 3. Currently pregnant, breastfeeding, or planning to become pregnant 4. Suffering from any serious neurological disorders or injuries, including but not limited to: any conditions related to increased intracranial pressure, space-occupying brain injuries, history of epilepsy, brain aneurysm, Parkinson's disease, Huntington's disease, multiple sclerosis, severe head trauma leading to loss of consciousness for 5 minutes or more; or has intracranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal objects inside or near the head (excluding the mouth) that cannot be safely removed. 5. Having a history of serious physical illnesses, organic brain disorders, and mental disorders caused by thyroid or other physical illnesses; or patients with severe physical illnesses, infectious diseases, and immune system disorders.

Design outcomes

Primary

MeasureTime frame
working memory volunm;Inhibition control;cognitive shifting;level of mind wandering during tasks performance;

Secondary

MeasureTime frame
working memory volunm during mind wandering;inhibition control during mind wandering;cognitive shifting during mind wandering;

Countries

China

Contacts

Public ContactWang Cheng

Zhejiang Normal University

wangchengpsych@aliyun.com+86 178 1554 5161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026